The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

  • See Evidence submitted by expert panel for details.

Variant: NM_002880.3(RAF1):c.770C>T (p.Ser257Leu)

CA235334

13957 (ClinVar)

Gene: RAF1
Condition: Noonan syndrome
Inheritance Mode: Autosomal dominant inheritance
UUID: 6eb64962-8efe-49ca-a5e1-499e4cddd80f

HGVS expressions

NM_002880.3:c.770C>T
NM_002880.3(RAF1):c.770C>T (p.Ser257Leu)
NM_001354689.1:c.770C>T
NM_001354690.1:c.770C>T
NM_001354691.1:c.527C>T
NM_001354692.1:c.527C>T
NM_001354693.1:c.671C>T
NM_001354694.1:c.527C>T
NM_001354695.1:c.428C>T
NR_148940.1:n.1185C>T
NR_148941.1:n.1185C>T
NR_148942.1:n.1185C>T
ENST00000251849.8:c.770C>T
ENST00000416093.1:c.*348C>T
ENST00000423275.5:c.*447C>T
ENST00000432427.2:n.407C>T
ENST00000442415.6:c.770C>T
ENST00000465826.5:n.14C>T
ENST00000491290.1:n.291C>T
NC_000003.12:g.12604200G>A
CM000665.2:g.12604200G>A
NC_000003.11:g.12645699G>A
CM000665.1:g.12645699G>A
NC_000003.10:g.12620699G>A
NG_007467.1:g.64980C>T

Pathogenic

Met criteria codes 5
PM6_Strong PS3 PP2 PM1 PM2

Evidence Links 5

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
RASopathy VCEP
The c.770C>T (p.Ser257Leu) variant in RAF1 has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; PMID 17603482,22389993, 23877478, 23312806, 25706034). In vitro functional studies provide some evidence that the p.Ser257Leu variant may impact protein function (PS3; PMID 17603482). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the RAF1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of RAF1 (PM1; PMID 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. ACMG/AMP criteria applied: PP2, PM1, PM2, PS3, PM6_Strong.
Met criteria codes
PM6_Strong
The c.770C>T (p.Ser257Leu) variant in RAF1 has been reported in the literature in at least 2 unconfirmed de novo occurrences in patients with clinical features of a RASopathy (PM6_Strong; PMID 17603482,22389993, 23877478, 25706034).

PS3
In vitro functional studies provide some evidence that the p.Ser257Leu variant may impact protein function (PS3; PMID 17603482).

PP2
The variant is located in the RAF1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581).
PM1
Furthermore, the variant is in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of RAF1 (PM1; PMID 29493581).

PM2
This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org).
Approved on: 2017-04-03
Published on: 2018-12-10
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.